Bioventus launched DUROLANE single-injection hyaluronic acid (HA) product in the U.S. to treat joint pain associated with knee osteoarthritis (OA). The product joins Bioventus U.S. orthobiologic portfolio that includes three-injection HA GELSYN-3™ and five-injection HA SUPARTZ FX™. Bioventus is now the only orthobiologics company in the U.S. offering 1-, 3- and 5-injection HA to treat knee OA.
The company received FDA approval for U.S. marketing of DUROLANE in late 3Q17. The product has been marketed ex-U.S. for over 15 years to treat pain associated with hip and knee OA.
In its year-end earnings call, Anika Therapeutics offered an update on progress for its CINGAL hyaluronic acid plus corticosteroid viscosupplement, noting that CINGAL is available in 10 markets ex-U.S., where >65,000 units have sold to date. Its rapid uptake in Canada, Germany and Italy has outpaced that of Anika’s MONOVISC in the same time period post-launch—suggesting that CINGAL may be perceived as clinically advantageous. One focus for 2018 is the build-up of a direct commercialization structure for CINGAL in the U.S., so it’s all ready to go for its anticipated 2019 launch.
Bioventus launched DUROLANE single-injection hyaluronic acid (HA) product in the U.S. to treat joint pain associated with knee osteoarthritis (OA). The product joins Bioventus U.S. orthobiologic portfolio that includes three-injection HA GELSYN-3™ and five-injection HA SUPARTZ FX™. Bioventus is now the only orthobiologics company in the U.S....
Bioventus launched DUROLANE single-injection hyaluronic acid (HA) product in the U.S. to treat joint pain associated with knee osteoarthritis (OA). The product joins Bioventus U.S. orthobiologic portfolio that includes three-injection HA GELSYN-3™ and five-injection HA SUPARTZ FX™. Bioventus is now the only orthobiologics company in the U.S. offering 1-, 3- and 5-injection HA to treat knee OA.
The company received FDA approval for U.S. marketing of DUROLANE in late 3Q17. The product has been marketed ex-U.S. for over 15 years to treat pain associated with hip and knee OA.
In its year-end earnings call, Anika Therapeutics offered an update on progress for its CINGAL hyaluronic acid plus corticosteroid viscosupplement, noting that CINGAL is available in 10 markets ex-U.S., where >65,000 units have sold to date. Its rapid uptake in Canada, Germany and Italy has outpaced that of Anika’s MONOVISC in the same time period post-launch—suggesting that CINGAL may be perceived as clinically advantageous. One focus for 2018 is the build-up of a direct commercialization structure for CINGAL in the U.S., so it’s all ready to go for its anticipated 2019 launch.
Copy to clipboard 
